New combo therapy aims to shrink hodgkin tumors with fewer side effects
NCT ID NCT05922904
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a mix of four drugs (brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine) in 25 people with untreated Hodgkin lymphoma that is either stage II with a large chest tumor or stage III/IV. The goal is to see if this combination can control the cancer while being safe. Participants will get the drugs in cycles, and doctors will adjust treatment based on PET scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.